Details of the Drug Reposition

General Information of This Drug (ID: DMR21Q3)

Drug Name
Clevudine   DMR21Q3
Synonyms
Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 4 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatitis B DISUFK2F 1E51 Phase 4 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00501124) Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04347915) The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. U.S. National Institutes of Health.